Investors and big pharma companies are waking up to the potential of techbio companies after years of avoidance, say experts ...
The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.
The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeutics’ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform.
As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug ...
From exploring the wonders of plants as a curious teen to leading global initiatives at SCIEX, Gitte Barknowitz has carved ...
At the forefront of precision dosing, Sharmeen leads DoseMe's efforts to transform personalized medicine from lab research to ...
Jane Koo, head of regulatory affairs at CTMC, plays an important role in accelerating the development and commercialization ...
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...
The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.
Evaxion’s proprietary AI-Immunology platform has shown in clinical trials that it can select clinically relevant cancer ...
The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback